Radiotheraphy and immunotherapy. Results of clinical trials of the combined approach
Vol 66 No 1 (2015), Oncology
Vol 66 No 1 (2015)

Radiotheraphy and immunotherapy. Results of clinical trials of the combined approach

Oncology
Published March 10, 2020
P. Sorochan
State Institution «Institute of Medical Radiology named after S.P. Grigoryev NAMS of Ukraine», Kharkov
I. Gromakova
State Institution «Institute of Medical Radiology named after S.P. Grigoryev NAMS of Ukraine», Kharkov
E. Sukhina
State Institution «Institute of Medical Radiology named after S.P. Grigoryev NAMS of Ukraine», Kharkov
N. Prokhach
State Institution «Institute of Medical Radiology named after S.P. Grigoryev NAMS of Ukraine», Kharkov
I. Gromakova
State Institution «Institute of Medical Radiology named after S.P. Grigoryev NAMS of Ukraine», Kharkov
PDF (Русский)

Keywords

cancer diseases
radiotherapy
immunotherapy

How to Cite

Sorochan, P., Gromakova, I., Sukhina, E., Prokhach, N., & Gromakova , I. (2020). Radiotheraphy and immunotherapy. Results of clinical trials of the combined approach. Medicine Today and Tomorrow, 66(1), 107–113. Retrieved from https://msz.knmu.edu.ua/article/view/475
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Results of clinical trials of the combined anticancer strategy including radiotheraphy and immunotherapy are reviewed.

PDF (Русский)

References

Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy / S. E. Finkelstein, F. Rodriguez, M. Dunn [et al.] // Immunotherapy. – 2012. – V. 4,

№ 4. – Р. 373–382.

Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients / S. E. Finkelstein, C. Iclozan, M. M. Bui [et al.] // Int. J. Radiat. Oncol. Biol. Phys. – 2012. – V. 82, № 2. – Р. 924–932.

Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma / K.-H. Chi, S.-J. Liu, C.-P. Li [et al.] // J. Immunother. – 2005. – V. 28, № 2. – Р. 129–135.

Formenti S. C. Systemic effects of local radiotherapy / S. C. Formenti, S. Demaria // Lancet Oncol. – 2009. – V. 10, № 7. – Р. 718–726.

Effects of preoperative immunochemoradiotherapy and chemoradiotherapy on immune responses in patients with rectal adenocarcinoma / S. Sadahiro, T. Suzuki, Y. Maeda [et al.] // Anticancer Res. – 2010. – V. 30, № 3. – Р. 993–999.

Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB–IVA cervical cancer with or without immunomodulator Z-100: a JGOG study / T. Sugiyama, K. Fujiwara, Y. Ohashi [et al.] // Ann. Oncol. – 2014. – V. 25, № 5. – Р. 1011–1017.

A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas / N. Butowski, K. R. Lamborn, B. L. Lee [et al.] // J. Neurooncol. – 2009. – V. 91, № 2. – Р. 183–189.

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study / J. D. Brody, W. Z. Ai, D. K. Czerwinski [et al.] // J. Clin. Oncol. – 2010. – V. 28, № 28. – Р. 4324–4332.

In situ vaccination against mycosis 29 fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase ½ study / Y. H. Kim, D. Gratzinger, C. Harrison [et al.] // Blood. – 2012. – V. 119, № 2. – Р. 355–363.

Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer / S. Adams, L. Kozhaya, F. Martiniuk [et al.] // Clin. Cancer Res. – 2012. – V. 18, № 24. – Р. 6748–6757.

Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer / J. L. Gulley, P. M. Arlen, A. Bastian [et al.] // Clin. Cancer Res. – 2005. – V. 11, № 9. – Р. 3353–3362.

Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer / J. L. Gulley, C. R. Heery, R. A. Madan [et al.] // Cancer Immunol. Immunother. – 2013. – V. 62, № 9. – Р. 1521–1531.

A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-tricom vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel / C. R. Heery, R. A. Madan, M. Bilusic [et al.] // J. Clin. Oncol. – 2013. – V. 31 (suppl. 6). – Abstract 102.

Immune-maximizing (IMAX) therapy for cancer: combination of dendritic cell vaccine and intensity-modulated radiation / Y. Shibamoto, M. Okamoto, M. Kobayashi [et al.] // Mol. Clin. Oncol. – 2013. – V. 1, № 4. – Р. 649–654.

TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors / N. Senzer, S. Mani, A. Rosemurgy [et al.] // J. Clin. Oncol. – 2004. – V. 22, № 4. – Р. 592–601.

A phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities // A. J. Mundt, S. Vijayakumar, J. Nemunaitis [et al.] // Clin. Cancer Res. – 2004. – V. 10, № 17. – Р. 5747–5753.

A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer / D. Citrin, K. Camphausen, B. J. Wood [et al.] // Oncology. – 2010. – V. 79, № 5–6. – Р. 382–388.

EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study / J. R. Hecht, J. J. Farrell, N. Senzer [et al.] // Gastrointest. Endosc. – 2012. – V. 75, № 2. – Р. 332–338.

Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer / K. J. Chang, T. Reid, N. Senzer [et al.] // Gastrointest. Endosc. – 2012. – V. 75, № 6. – Р. 1139–1146.

A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation / T. Y. Seiwert, T. Darga, D. Haraf [et al.] // Ann. Oncol. – 2013. – V. 24, № 3. – Р. 769–776.

Randomized phase III multiinstitutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results / J. M. Herman, A. T. Wild, H. Wang [et al.] // J. Clin. Oncol. – 2013. – V. 31, № 7. – Р. 886–894.

Phase 1 study of stereotactic body radiotherapy and interleukin-2–tumor and immunological responses / S. K. Seung, B. D. Curti, M. Crittenden [et al.] // Sci. Transl. Med. – 2012. – V. 4, № 137: 137ra74.

Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis / M. Kovacsovics-Bankowski, L. Chisholm, J. Vercellini [et al.] // Journal for ImmunoTherapy of Cancer. – 2013. – V. 1 (suppl. 1). – P. 255.

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an openlabel, multicenter phase I/II study / S. F. Slovin, C. S. Higano, O. Hamid [et al.] // Ann. Oncol. – 2013. – V. 24, № 7. – Р. 1813–1821.

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial / E. D. Kwon, C. G. Drake, H. I. Scher [et al.] // Lancet Oncol. – 2014. – V. 15, № 7. – Р. 700–712.

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy / A. M. Grimaldi, E. Simeone, D. Giannarelli [et al.] // Oncoimmunology. – 2014. – V. 3: e28780.

Current clinical trials testing combinations of immunotherapy and radiation / M. Crittenden, H. Kohrt, R. Levy [et al.] // Semin. Radiat. Oncol. – 2015. – V. 25, № 1. – Р. 54–64.